Clover Health Investments, Corp.
CLOV Healthcare Healthcare Plans
Clover Health Investments, Corp.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, up 40.3% from fiscal 2024.
- Revenue
- +52.9%
- EPS
- +350.0%
- Free cash flow
- +508.9%
Quarter to September 2026, against a year earlier
Follow CLOV
Alert me
Clover Health Investments, Corp. (CLOV) P/S ratio
As of 6 November 2026, Clover Health Investments, Corp. (CLOV) trades at a P/S ratio of 0.9×. Over the past ten years it has ranged from 0.0× (December 2023) to 42.5× (August 2023); the current reading is higher than 60% of that period. That is above the Healthcare Plans industry median of 0.4× and below the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 0.6× | (44.47%) |
| FY2024 | 1.1× | 206.59% |
| FY2023 | 0.4× | (11.00%) |
| FY2022 | 0.4× | (60.46%) |
| FY2021 | 1.0× | (52.79%) |
| FY2020 | 2.2× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Sep 2026 | 0.8× | (24.58%) |
| Jun 2026 | 1.1× | 166.84% |
| Mar 2026 | 0.4× | (33.53%) |
| Dec 2025 | 0.6× | (29.33%) |
| 23 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| CNC Centene Corporation compare | 0.2× |
| MOH Molina Healthcare, Inc compare | 0.2× |
| CI Cigna Group compare | 0.3× |
| ALHC Alignment Healthcare, Inc. compare | 0.3× |
| HUM Humana Inc. compare | 0.3× |
| ELV Elevance Health, Inc. compare | 0.5× |
| OSCR Oscar Health, Inc. compare | 0.5× |
| CLOV Clover Health Investments, Corp. | 0.9× |
| PGNY Progyny, Inc. compare | 2.0× |
| Healthcare Plans industry median | 0.4× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on CLOV
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement